<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733638</url>
  </required_header>
  <id_info>
    <org_study_id>Viz-ICH-02</org_study_id>
    <nct_id>NCT04733638</nct_id>
  </id_info>
  <brief_title>ADVANCE- Automated Detection and Volumetric Assessment of ICH</brief_title>
  <official_title>Automated Detection and Volumetric Assessment of Intracerebral Hemorrhage Using Artificial Intelligence- Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viz.ai, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viz.ai, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the performance of the Viz ICH VOLUME algorithm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the performance of the Viz ICH VOLUME algorithm to:&#xD;
&#xD;
        1. detect the presence of ICH on brain imaging,&#xD;
&#xD;
        2. measure the volume of ICH on brain imaging,&#xD;
&#xD;
        3. and to assess the algorithm processing time,&#xD;
&#xD;
        4. and the difference in time to notification, time to treatment, and clinical outcomes in&#xD;
           comparison to standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Algorithm Performance</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>Sensitivity and specificity of Viz ICH VOLUME in detecting ICH compared to standard of care evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Algorithm Processing Time</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>Total run time in minutes for the algorithm to process the CT scan following receipt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Notification</measure>
    <time_frame>Up to 10 minutes</time_frame>
    <description>Time in minutes from CT imaging to time an interventionalist was notified</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment</measure>
    <time_frame>up to 1 day (1440 minutes)</time_frame>
    <description>Time in minutes from CT imaging to start time of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>Hospital admit to discharge, up to 30 days</time_frame>
    <description>Number of days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In Hospital Complications</measure>
    <time_frame>Hospital admit to discharge, up to 30 days</time_frame>
    <description>Occurrence of stroke-related or stroke treatment-related complications while in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) at Discharge and 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire. A score of 0 is a patient with no residual symptoms. Scores increase with severity to 5 which equals severe disability.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Pre-Viz ICH VOLUME</arm_group_label>
    <description>Patient data collected prior to Viz ICH VOLUME implementation, utilized as a control data set</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post-Viz ICH VOLUME</arm_group_label>
    <description>Patient data collected post-Viz ICH VOLUME implementation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Viz ICH VOLUME</intervention_name>
    <description>Viz ICH VOLUME software is a module that identifies and segments Intraparenchymal Hemorrhage (IPH) from NCCT imaging. This software is for investigational use in the study and is not FDA cleared. For subjects who undergo a brain scan, Viz will use deep learning algorithms to analyze computed tomography (CT) or magnetic resonance (MR) images of the brain for ICH in parallel to standard of care image interpretation. If a suspected ICH is detected, Viz will perform an automatic volumetric analysis and will send a notification to a specialist, such as a neurointerventionalist or a neurosurgeon. Notifications prompt the specialist to review the patient's case. Additionally, non-diagnostic previewing of DICOM images, and HIPAA-compliant text messaging and phone calls are available in the software platform. Viz ICH VOLUME is not intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man.</description>
    <arm_group_label>Post-Viz ICH VOLUME</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients, that meet eligibility criteria, undergoing imaging for a&#xD;
        suspected acute stroke or intracranial hemorrhage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (18 and older)&#xD;
&#xD;
          -  Presenting with symptoms suspicious for an acute stroke / intracranial hemorrhage&#xD;
&#xD;
          -  Having a complete imaging data set including NCCT +/- MRI, CTA and/or MRA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with poor or incomplete brain imaging.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moleen Madziva</last_name>
    <role>Study Director</role>
    <affiliation>Director of Clinical Affairs at Viz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swedish Medical Center Healthone</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prisma Health Upstate</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 27, 2021</study_first_submitted>
  <study_first_submitted_qc>January 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Intelligence</keyword>
  <keyword>ICH</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

